- LXRP, a drug delivery platform innovator, has been awarded two new patent grants in the U.S. and expects three more from Australia
- Company already has more than 40 patent awards or applications from 40 countries globally; it is preparing new patent application filings and predicts more patent awards this year
- LXRP received $63,000 from the exercise of 450,000 warrants previously granted to third parties
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is growing its patent portfolio with two more patent grants in the U.S., predicting three more from Australia, and it is currently preparing new patent application filings as it projects more patent awards this year. It already has more than 40 patent applications or awards from more than 40 countries worldwide (http://nnw.fm/cj1KT).
The total, once granted, would be four patents in the U.S. and four in Australia. All eight are for the family of “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” The development represents the first time that…
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]